In summary, consistent with our hypothesis, CFTR modulator drugs such as Tezacaftor, with great promise for performance, may be repurposed for use in treating CFTR-deficient colorectal cancer patients in both CF and non-CF patients. Here, CFTR is linked to colorectal cancer.